ReviewGenome medicine2013
Intra-tumor heterogeneity: lessons from microbial evolution and clinical implications.
Review in Genome medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Immunotherapy-induced microsatellite instability status shift in recurrent perihilar cholangiocarcinoma: A case report.Human vaccines & immunotherapeutics · 2025Article
- Therapeutic T cells with 3-in-1 strategy for the treatment of biliary tract cancer.Cell reports. Medicine · 2025Article
- Drug resistance and tumor heterogeneity: cells and ensembles.Biophysical reviews · 2025Review
- Recombinant Human Adenovirus Type 5 (H101) Intra-Tumor Therapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer: Genomic Profiling Relating to Clinical Efficacy.Drug design, development and therapy · 2023Article
- Pragmatic Expectancy on Microbiota and Non-Small Cell Lung Cancer: A Narrative Review.Cancers · 2022Review
- Can Environmental Manipulation Help Suppress Cancer? Non-Linear Competition Among Tumor Cells in Periodically Changing Conditions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- Deep learning with multimodal representation for pancancer prognosis prediction.Bioinformatics (Oxford, England) · 2019Article
- Genome landscapes of rectal cancer before and after preoperative chemoradiotherapy.Theranostics · 2019Article
- Predicting the evolution of Escherichia coli by a data-driven approach.Nature communications · 2018Article
- Experimental Design, Population Dynamics, and Diversity in Microbial Experimental Evolution.Microbiology and molecular biology reviews : MMBR · 2018Review
- Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.Disease models & mechanisms · 2018Article
- Resource competition promotes tumour expansion in experimentally evolved cancer.BMC evolutionary biology · 2017Article
- Reconstructing cancer karyotypes from short read data: the half empty and half full glass.BMC bioinformatics · 2017Article
- Non-cell-autonomous effects yield lower clonal diversity in expanding tumors.Scientific reports · 2017Article
- Tracking the evolution of cancer cell populations through the mathematical lens of phenotype-structured equations.Biology direct · 2016Article
- Article
- Promises and pitfalls for recombinant oligoclonal antibodies-based therapeutics in cancer and infectious disease.Current opinion in immunology · 2016Review
- A microRNA biomarker of hepatocellular carcinoma recurrence following liver transplantation accounting for within-patient heterogeneity.BMC medical genomics · 2016Article
- Toward precision medicine of breast cancer.Theoretical biology & medical modelling · 2016Review
- Epidermal growth factor receptor immunohistochemistry: new opportunities in metastatic colorectal cancer.Journal of translational medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple subclonal populations of tumor cells can coexist within the same tumor. This intra-tumor heterogeneity will have clinical implications and it is therefore important to identify factors that drive or suppress such heterogeneous tumor progression. Evolutionary biology can provide important insights into this process. In particular, experimental evolution studies of microbial populations, which exist as clonal populations that can diversify into multiple subclones, have revealed important evolutionary processes driving heterogeneity within a population. There are transferrable lessons that can be learnt from these studies that will help us to understand the process of intra-tumor heterogeneity in the clinical setting. In this review, we summarize drivers of microbial diversity that have been identified, such as mutation rate and environmental influences, and discuss how knowledge gained from microbial experimental evolution studies may guide us to identify and understand important selective factors that promote intra-tumor heterogeneity. Furthermore, we discuss how these factors could be used to direct and optimize research efforts to improve patient care, focusing on therapeutic resistance. Finally, we emphasize the need for longitudinal studies to address the impact of these potential tumor heterogeneity-promoting factors on drug resistance, metastatic potential and clinical outcome.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.